Dr. M .P. Ram Prabhu

• MBBS: Madurai Medical College, The Tamil Nadu Dr. M.G.R. Medical University, Tamil Nadu (1996 - 2000).
• MD (General Medicine): Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry (2003 - 2006).
• DM (Medical Oncology): All India Institute of Medical Sciences (AIIMS), New Delhi (2008 - 2011).

• Specialised training in Bone Marrow Transplantation at AIIMS, New Delhi.
• Advanced training in HIPEC for peritoneal surface malignancies.

• Certified in Essential Good Clinical Practice (GCP).
• Member of key oncological societies in India.

• Breast Cancer (Triple Negative & Hormone Positive)
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Pancreas Cancer
• Ovarian Cancer
• Cervical Cancer
• Uterine Cancer
• Head & Neck Cancers
• Prostate Cancer
• Bladder Cancer
• Kidney Cancer
• Leukaemia
• Lymphoma
• Myeloma)
• Brain Tumours
• Musculoskeletal Tumours

• Medical Oncology
• Haemato-Oncology
• Paediatric Oncology (Select cases)
• Geriatric Oncology

• Bone Marrow Transplantation (BMT)
• HIPEC (Hyperthermic Intraperitoneal Chemotherapy)
• Immunotherapy
• Targeted Therapy
• Intensive Chemotherapy

Current & Past Hospital Affiliations:

• Current Affiliation: Senior Consultant – Medical Oncology, Iswarya Hospital, OMR Chennai (Present).
• Past Affiliations:
• Senior Consultant – Medical Oncology, Gleneagles Global Hospitals, Chennai (8 years).
• Consultant – Medical Oncology, MIOT Hospitals, Chennai (6 years).
• Research Officer, AIIMS New Delhi (2007).

Academic & Research Roles:
Dr. Prabu has a strong academic background, having served as a Research Officer at AIIMS on projects involving Gastrointestinal Stromal Tumours (GIST). He has conducted significant thesis work on Chronic Myeloid Leukaemia (CML) and Triple-Negative Breast Cancer.

Key Achievements & Contributions:

• Successfully established protocols for advanced chemotherapy and BMT in tertiary care settings in Chennai.
• Contributed to the understanding of EGFR expression in triple-negative breast cancer through his DM thesis.
• Recognised for handling complex, relapsed, and refractory cancer cases with high success rates.

• Recognised as a leading oncologist in India for his contributions to Medical Oncology in Southern India.
• Notable presenter at national oncology conferences regarding breast cancer subtypes and treatment outcomes.
• Acknowledged for high patient satisfaction and ethical medical practice across tenure at Gleneagles Global and MIOT Hospitals

Published Papers in Medical Journals:

• Lymphocytosis and chronic leukaemia – Natl Med J India (2009).
• Systemic reaction to leucovorin in a child with lymphoblastic lymphoma suggestive of hypersensitivity – Pediatr Blood Cancer (2009).
• Autologous hematopoietic stem cell transplantation-what determines the outcome: an experience from North India – Ann Hematol (2011).
• A study of triple-negative breast cancer at a cancer institute in India – J Clin Oncol (2011).
• PNET spine: morbid and mortal, but ignored till late – J Pediatr Hematol Oncol (2012).
• Primary cardiac angiosarcoma with good response to Paclitaxel – J Thorac Oncol (2011).

Ongoing Clinical Trials Participation:
Dr. Prabu actively keeps abreast of the latest clinical trials involving Immunotherapy agents and targeted drugs for solid tumours to offer patients access to cutting-edge treatments.

Notable Cases Handled:

• Successfully treated a young patient with advanced Acute Myeloid Leukaemia using intensive chemotherapy followed by a bone marrow transplant.
• Managed a complex case of recurrent ovarian cancer using HIPEC (heated chemotherapy), significantly extending the patient's disease-free survival.
• Provided long-term remission for a metastatic lung cancer patient through the precise application of targeted therapy.

Patient Testimonials:

"I was diagnosed with stage 3 lymphoma and was terrified. Dr. M. P. Ram Prabu explained the treatment plan with such clarity and calmness that half my fear vanished. His expertise in chemotherapy is evident, but his kindness is what makes him special. I am now in remission and grateful to him." – S. Narayan

"We travelled from Bengal to Chennai for my father's treatment. Dr. Prabu is undoubtedly a top oncologist in India. He did not rush us into surgery but suggested a combination of immunotherapy and chemo which worked wonders. His team at Iswarya Hospital is excellent." – Anjali D.

"Dr. Ram Prabu managed my breast cancer treatment. He is very up-to-date with the latest medicines. He suggested a genetic test that changed my treatment course and saved me from unnecessary strong chemo. Highly recommended." – Mrs. V. K.

• Patient-Centred Care:Dr. Prabu believes in a holistic approach where the patient's quality of life is as important as the cure. He spends time counselling patients and families, ensuring they understand the diagnosis and the rationale behind the chosen therapy.
• Technology & Innovation:As a leading oncologist in India, he is a strong advocate for Precision Oncology. He integrates the latest advancements in genomic sequencing to tailor treatments (Targeted Therapy and Immunotherapy) specifically to the molecular profile of the patient's tumour, moving away from the "one-size-fits-all" approach.

The following table provides an estimated cost range for various cancer treatments in India. These costs are indicative and vary based on the stage of cancer, the specific drugs used, and the duration of the hospital stay.

For appointment booking and to get a personalised cost estimate, you can connect with the Cancer Rounds team.

• Language Support:The Cancer Rounds team provides dedicated language interpretation services to ensure seamless communication between international patients and Dr. M. P. Ram Prabu.
• Visa & Travel Assistance:We assist patients with medical visa invitation letters, flight itineraries, airport transfers, and accommodation arrangements near the hospital for long-term treatment stays.
• Pre-treatment Virtual Consultations:International patients can avail of video consultations with Dr. Prabu via Cancer Rounds to discuss medical reports and treatment feasibility before travelling to India.